U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)U.S. Army Medical Research and Materiel Command
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) is the U.S. Department of Defense (DoD) lead medical research laboratory on biological threats resulting in medical solutions to protect military service members and the greater public.
The facility contains the only Department of Defense laboratory equipped with a BSL 4 laboratory for highly hazardous infectious agents requiring maximum containment.
USAMRIID develops rapid diagnostic assays for to protect the warfighter against biological threats. They additionally evaluate and develop diagnostic instruments and technologies for use in forward field medical laboratories and with the Joint Biological Agent Identification and Detection System (JBAIDS), the diagnostics platform used across the DoD.
USAMRIID performs the necessary studies required to pre-position assays for Emergency Use Authorization (EUA) from the FDA in the event of a pandemic or outbreak, as happened during the Ebola outbreak
Currently, USAMRIID-developed vaccine candidates for anthrax and ricin are in clinical testing. Other vaccine candidates for plague, botulinum neurotoxins A and B, and Venezuelan equine encephalitis are in advanced development.
Vaccines for staphylococcal enterotoxins A and B, hantaviruses, and five additional serotypes of botulinum neurotoxins (designated C-G) are soon to be transitioned. About a dozen other vaccines developed at USAMRIID are maintained in Investigational New Drug status and are used to immunize at-risk personnel in the lab and in the field when necessary.
The Institute is also working to develop therapeutics for a number of agents, such as Ebola virus, plague, several toxins, and orthopoxviruses, including smallpox.
USAMRIID additionally serves as a National-Level Laboratory, along with the Centers for Disease Control and Prevention (CDC), within the United States’ Laboratory Response Network (LRN). The LRN is network of local, state and federal public health, hospital-based, food testing, veterinary and environmental testing laboratories that provide laboratory diagnostics and the capacity to respond to biological and chemical threats and other public health emergencies.
USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
Editor’s Picks: Select articles related to USAMRIID . Links may lead to external sites.
If any science lab should be poised to tackle the current outbreak, it’s the US Army Institute of Infectious Diseases, or USAMRIID.
Marketed under the brand name JYNNEOS, the vaccine against monkeypox and smallpox was developed by Bavarian Nordic and tested by USAMRIID.
The Inspector General assessment was announced in a 12 Aug 2019 memorandum.
The only Biosafety Level 4 laboratory in the DoD has ceased research operations on high-risk pathogens after failing to meet Federal biosafety requirements. The move results from several actions recently taken by the CDC in response to concerns about USAMRIID’s past management of its Biological Select Agents and Toxins (BSAT) research program.
- Research Halted at USAMRIID Over Biosafety Issues (Aug 2019)
- USAMRIID Temporarily Halts Activity at BSL-3 and BSL-4 Laboratories (Jun 2018)
- Frederick Researcher Continues Grandfather’s Work On Zika Virus (Feb 2016)
- Antiviral Compound Protects Nonhuman Primates Against Ebola Virus (Feb 2015)
- Army Scientists Help Develop Ebola Vaccines (Nov 2015)
- Host Response Profiling of Burkholderia, Y. Pestis (Jan 2015)
- NanoViricides, USAMRIID Sign CRADA for Ebola Drug Testing (Nov 2014)
- USAMRIID Scientist at Forefront of Developing Vaccine for Ebola (Aug 2014)
- Luminex Technology Supporting USAMRIID Ebola Response (Aug 2014)
- USAMRIID Providing Laboratory Support to Ebola Outbreak (Jul 2014)
- USAMRIID Leads Effort on Viral Genome Sequencing Standards (Jun 2014)
- Broad-Spectrum Antiviral Effective Against Ebola, MERS-CoV (Mar 2014)